Somaxon's Silenor approved in US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Somaxon Pharmaceuticals' insomnia drug Silenor (low-dose doxepin) after a long approval process. The drug is authorised for the treatment of both transient and chronic insomnia characterised by difficulty with sleep maintenance in adults and elderly patients.